GeniePlex enabled simultaneous quantification of NK cell cytotoxic effector molecules at varying E:T ratios — providing the mechanistic readout for a DR5-specific TRAIL variant’s enhanced anti-tumour activity.

Combined with scRNA-seq, demonstrated that SARS-CoV-2-induced epithelial cytokines and PROS1 jointly shape monocyte phenotype toward MHC-II-high antigen-presenting state — mechanism for mild vs severe COVID-19 inflammatory regulation.

Intermittent mechanical actuation at 68.9 kPa significantly reduced pro-fibrotic IL-1β and upregulated anti-inflammatory IL-10 after 14 days — informs the design of implantable medical devices that actively modulate foreign body response.

Quantified in vivo cytokine response in MOF nanomedicine safety screening — UiO-66-AP and PCN-222-P showed only transient IL-6 elevation at 24h returning to baseline by day 14, validating them as biocompatible carriers.

Composite acute inflammation score (CXCL-10×CCL-2/IL-10) significantly predicted peripheral sensitization (R²=0.642); cartilage degeneration + chronic inflammation explained 82.7% of central sensitization variance. Provides a molecular framework for OA pain phenotyping.

Functional validation of Kupffer cell integration into 3D liver spheroids — LPS-induced IL-6 and TNF-α secretion was Kupffer-cell-dependent while MCP-1 was hepatic-stellate-cell-derived, providing cell-type-specific cytokine attribution in a NAFLD/NASH drug-screening platform.

CK2 inhibitor CHR (37 mg/kg, 4-day pre-treatment) reduced TNF-α-induced IL-6, MCP-1, IP-10, KC, and TNF-α in mouse cortex and hippocampus — central evidence that CK2 inhibition rescues neuroinflammation in vivo.

GeniePlex measurements were central evidence in two contexts: (a) implant biocompatibility — no significant systemic IL-6/TNF-α elevation post-implantation, and (b) in vivo Th1/Th17 immune activation following scaffold-mediated lentiviral delivery, correlating with reduced tumour size.

Two-fold+ increases in IL-2, IFN-γ, TNF-α, IL-17A, IL-21, IL-22 correlating with reduced tumour size and anti-tumour T-cell response after scaffold-delivered lentiviral therapy.

Claudin-6 knockdown abrogated the protective anti-tumour cytokine profile measured by GeniePlex — direct evidence linking claudin-6 expression to breast cancer immune evasion mechanisms.

Quantitative characterisation of cytokine output from engineered TCR T cell populations — supporting GeniePlex as a functional readout for TCR engineering pipelines.

Validation of custom rat 8-plex on muscle tissue homogenate as a readout for skeletal-muscle pharmacology studies — extending GeniePlex into tissue-direct compartmental cytokine measurements.